ANDA 211343, held by Changzhou Pharm. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 211343 (Doxycycline Hyclate), held by Changzhou Pharm, was first approved by FDA on Oct 9, 2019, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline and other antibacterial drugs, doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 9, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Doxycycline HyclateEQ 100MG BASE · tablet;oral | Doxycycline Hyclate | Rx |
| Sep 14, 2026 | Supplement 10Labeling · Standard review | Approved | None posted |
| Mar 31, 2025 | Supplement 9Labeling · Standard review | Approved | None posted |
| Sep 6, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Oct 9, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters